The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Volume 134, Issue 12
Displaying 1-8 of 8 articles from this issue
Erratum
Obituary
Seminar for Medical Education
Original Articles
Review
  • Kowichi Jimbow, Tokimasa Hida, Akinori Kawakami, Shosuke Ito, Kazumasa ...
    2024 Volume 134 Issue 12 Pages 3017-3034
    Published: November 20, 2024
    Released on J-STAGE: November 20, 2024
    JOURNAL RESTRICTED ACCESS

    Systemic target immuno-therapeutics and immune checkpoint inhibitors have been successfully introduced for high-risk unresectable white Caucasian melanomas. However, darker skinned Asian and Japanese patients do not receive these benefits, and new approaches for target therapy are urgently needed. We developed a new melanoma-targeting chemo-thermo-immuno-therapy (CTI therapy) by producing 17 melanogenesis substrates and selecting N-propionyl cysteaminylphenol (NPrCAP) through selective drug delivery and cytotoxicity to melanoma cells. NPrCAP generated reactive free radicals with tyrosinase and resulted in chemical cytotoxicity with production of many apoptotic and a few necrotic cells (chemo-immunotherapy). NPrCAP was further conjugated with magnetite nanoparticles and produced heat shock protein and necrotic cells after exposure to alternating magnetic fields (thermo-immunotherapy). The combined chemo-thermo-immuno (CTI) -therapy has been successfully tested in growth inhibition of experimental murine metastatic melanomas. Preliminary clinical trials have also shown significant regression of unresectable distant human melanomas and increased the life span of patients.

    Download PDF (2334K)
Abstracts
feedback
Top